Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:1728-1735
doi: 10.1161/CIRCULATIONAHA.105.547836
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kathiresan, S.
Right arrow Articles by O’Donnell, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kathiresan, S.
Right arrow Articles by O’Donnell, C. J.
Related Collections
Right arrow Clinical genetics
Right arrow Epidemiology
Right arrow Coagulation and fibronolysis
Right arrow Genomics
Right arrow Fibrinolysis

(Circulation. 2005;112:1728-1735.)
© 2005 American Heart Association, Inc.


Epidemiology

Comprehensive Survey of Common Genetic Variation at the Plasminogen Activator Inhibitor-1 Locus and Relations to Circulating Plasminogen Activator Inhibitor-1 Levels

Sekar Kathiresan, MD*; Stacey B. Gabriel, PhD*; Qiong Yang, PhD; Amy L. Lochner, AB; Martin G. Larson, ScD; Daniel Levy, MD; Geoffrey H. Tofler, MD; Joel N. Hirschhorn, MD, PhD; Christopher J. O’Donnell, MD, MPH

From the National Heart, Lung, and Blood Institute’s Framingham Heart Study (S.K., Q.Y., M.G.L, D.L., C.J.O.), Framingham, Mass; Broad Institute of Harvard University and Massachusetts Institute of Technology (S.K., S.B.G., A.L.L., J.N.H., C.J.O.), Cambridge, Mass; Department of Biostatistics (Q.Y.), Boston University School of Public Health; Department of Neurology (Q.Y.), Boston University School of Medicine; Department of Mathematics and Statistics (M.G.L.), Boston University, Boston, Mass; Royal North Shore Hospital (G.H.T.), Sydney, Australia; Divisions of Genetics and Endocrinology (J.N.H.), Children’s Hospital and Department of Genetics, Harvard Medical School, Boston, Mass; and Cardiology Division (S.K., C.J.O.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Christopher J. O’Donnell, MD, MPH, Framingham Heart Study, 73 Mt Wayte Ave, Suite No. 2, Framingham, MA 01702-5827. E-mail odonnellc{at}nhlbi.nih.gov

Received July 15, 2004; de novo received March 8, 2005; revision received May 31, 2005; accepted June 17, 2005.

Background— Using a linkage disequilibrium (LD)–based approach, we sought to comprehensively define common genetic variation at the plasminogen activator inhibitor-1 (PAI-1) locus and relate common single nucleotide polymorphisms (SNPs) and haplotypes to plasma PAI-1 levels.

Methods and Results— In reference pedigrees, we defined LD structure across a 50-kb genomic segment spanning the PAI-1 locus via a dense SNP map (1 SNP every 2 kb). Eighteen sequence variants that capture underlying common genetic variation were genotyped in 1328 unrelated Framingham Heart Study participants who had plasma PAI-1 antigen levels measured. Regression analyses were used to examine associations of individual SNPs and of inferred haplotypes with multivariable-adjusted PAI-1 levels. Two genetic variants, SNP rs2227631 and the 4G/5G polymorphism, were strongly associated (P<0.0001) with PAI-1 levels. SNP rs2227631 is in tight LD (D'=0.97, r2=0.78) with the 4G/5G polymorphism, which makes it difficult to distinguish which of these 2 polymorphisms is responsible for the association with PAI-1 levels. In stepwise analysis considering all polymorphisms tested, 3 SNPs, rs2227631 (or the correlated 4G/5G polymorphism), rs6465787, and rs2227674, each explained 2.5%, 1%, and 1%, respectively, of the residual variance in multivariable-adjusted PAI-1 levels (stepwise P<0.0001, P=0.04, and P=0.03, respectively). A single common haplotype, at 50% frequency among Framingham Heart Study participants, was strongly associated with higher PAI-1 levels (haplotype-specific P=0.00001). The susceptibility haplotype harbors the minor alleles of SNP rs2227631 and the 4G/5G polymorphism.

Conclusions— Three sequence variants at the PAI-1 locus, in sum, explain {approx}5% of the residual variance in multivariable-adjusted PAI-1 levels. For quantitative cardiovascular traits such as circulating biomarkers, defining LD structure in a candidate gene followed by association analyses with both SNPs and haplotypes is an effective approach to localize common susceptibility alleles.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
BloodHome page
D. French, L. H. Hamilton, L. A. Mattano Jr, H. N. Sather, M. Devidas, J. B. Nachman, and M. V. Relling
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group
Blood, May 1, 2008; 111(9): 4496 - 4499.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Yende, D. C. Angus, J. Ding, A. B. Newman, J. A. Kellum, R. Li, R. E. Ferrell, J. Zmuda, S. B. Kritchevsky, T. B. Harris, et al.
4G/5G Plasminogen Activator Inhibitor-1 Polymorphisms and Haplotypes Are Associated with Pneumonia
Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1129 - 1137.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague
Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study
Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2250 - 2257.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. D. Sternlicht, A. M. Dunning, D. H. Moore, P. D.P. Pharoah, D. G. Ginzinger, K. Chin, J. W. Gray, F. M. Waldman, B. A.J. Ponder, and Z. Werb
Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 Expression.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2107 - 2114.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Kathiresan, M. G. Larson, R. S. Vasan, C.-Y. Guo, P. Gona, J. F. Keaney Jr, P. W.F. Wilson, C. Newton-Cheh, S. L. Musone, A. L. Camargo, et al.
Contribution of Clinical Correlates and 13 C-Reactive Protein Gene Polymorphisms to Interindividual Variability in Serum C-Reactive Protein Level
Circulation, March 21, 2006; 113(11): 1415 - 1423.
[Abstract] [Full Text] [PDF]